Ares Life Sciences in the acquisition of Albion Medical Holdings, Inc., including its wholly owned subsidiary GREER Laboratories, Inc., a leader in allergy immunotherapy in the United States.

Mr. Graebner’s high-yield representations include:

Stena AB in its US$350 million high-yield offering of 5.75% senior secured notes due 2024 and US$650 million term loan;

LM Group Holding A/S in its issuance of senior secured notes as well as its subsequent consent solicitation and issuance of green bonds;

TMF Group Holding B.V. in its (i) offering of €405 million in floating-rate senior secured notes and €175 million fixed-rate senior notes, and (ii) additional offering of €65 million in floating-rate senior secured notes and €20 million fixed-rate senior notes;

Zobele Holding S.p.A. in its offering of senior secured notes; and

HellermannTyton Finance PLC in its offering of high-yield bonds and subsequent IPO.

Mr. Graebner’s other capital markets representations include:

Marine Harvest ASA in its listing on the New York Stock Exchange;

Doughty Hanson in its disposal of Balta to Lone Star Funds through a dual track process; and

Doughty Hanson in its disposal of Eurofiber for €875 million to Antin Infrastructure Partners through a dual track process.

Mr. Graebner also has advised BHP Billiton, TORM A/S and Central European Distillation Corporation in connection with U.S. securities law matters.